US Patent 7,868,044: Claim Scope, Expiration, Orange Book Status, and Adapalene Patent Landscape

US Patent 7,868,044 protects methods of treating acne with a topical composition containing 0.3% adapalene as the sole active anti-acne ingredient. Its claims cover five dosage-form platforms: aqueous gels, aqueous cream gels, creams, aqueous lotions, and spray solutions. The patent does not broadly protect adapalene itself, all adapalene concentrations, or combination products containing benzoyl peroxide or antibiotics.

The patent’s 20-year term was tied to the underlying nonprovisional filing and reached its nominal expiration in 2021. As a result, US 7,868,044 is no longer a meaningful barrier to US generic entry, subject to confirmation of the official term-adjustment and terminal-disclaimer records in USPTO Patent Center. The commercial relevance of the patent is historical and claim-specific rather than prospective.

What does US Patent 7,868,044 protect?

The patent protects a method of treating acne by applying a topical formulation containing:

Required limitation	Scope
Active ingredient	Adapalene, chemically identified as 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid
Concentration	0.3% by weight
Therapeutic use	Treatment of acne, including common acne in dependent claims
Active-ingredient limitation	Adapalene must be the only active anti-acne ingredient
Administration	Topical administration to the affected skin
Formulation type	Gel, cream gel, cream, aqueous lotion, or spray solution
Excipients	Must satisfy the applicable independent or dependent claim limitations
Claim structure	Method-of-treatment claims, not composition claims

The central limitation is the combination of 0.3% adapalene, monotherapy for acne, and a specified topical vehicle. A product containing 0.1% adapalene falls outside the concentration limitation. A product containing adapalene plus benzoyl peroxide or an antibiotic falls outside the “only active anti-acne ingredient” limitation, although other patents may cover those combination products.

How are claims 1 through 41 organized?

The claims divide into five principal formulation families.

Claim family	Formulation	Principal claim coverage
Claims 1-6, 34, 40-41	Aqueous gel	0.3% adapalene gel with selected gelling agents and specific Carbomer 940 or xanthan gum formulations
Claims 7-12, 35	Aqueous cream gel	0.3% adapalene cream gel using Simulgel 600 PHA, Pemulen TR1, or related vehicles
Claims 13-18, 36	Cream	0.3% adapalene cream with oil, silicone, fatty, or emulsifying components
Claims 19-28, 37, 39	Aqueous lotion	0.3% adapalene lotion containing specified humectants, oils, emulsifiers, polymers, or related excipients
Claims 29-33, 38	Spray solution	0.3% adapalene spray solution containing caprylic/capric triglycerides

Claims 2, 8, 14, 20, and 30 limit the treatment to common acne. Claims 34 through 38 add broad categories of inert additives. Claims 40 and 41 narrow the aqueous-gel group to carbomer, including Carbomer 940.

What is the broadest enforceable concept in claim 1?

Claim 1 is the principal aqueous-gel claim. It requires:

Treatment of acne in an individual.
Topical administration.
A pharmaceutical aqueous gel.
0.3% adapalene by weight.
Adapalene as the only active anti-acne ingredient.
At least one listed gel-forming or emulsifying component.

The excipient Markush group includes:

Carbomers.
Polymeric emulsifying agents.
Polysaccharidic biopolymers.
Gums.
Alginates.
Modified celluloses.
Starch-derived products.
A mixture of polysorbate 80 and isohexadecane.
Acrylamide/sodium acryloyldimethyltaurate.
Mixtures of these materials.

The claim is broad across aqueous-gel technologies, but it is narrow in three commercially important respects: concentration, monotherapy, and dosage form.

A competing 0.3% adapalene gel would present a claim issue if it used any qualifying gelling or polymeric emulsifying agent. A formulation change from gel to cream, lotion, or spray would avoid claim 1 but could implicate another independent claim.

What formulations are specifically protected by claims 3 through 6?

Claims 3 through 6 cover two detailed aqueous-gel formulations.

Carbomer 940 gel

Claim 4 recites, per gram:

Ingredient	Amount
Adapalene	3 mg
Carbomer 940	11 mg
Disodium edetate	1 mg
Methyl paraben	2 mg
Poloxamer 124	2 mg
Propylene glycol	40 mg
Sodium hydroxide	Quantity sufficient for pH 5.0 ± 0.3
Purified water	Quantity sufficient to 1 g

This is a highly specific formulation claim. A generic product using the same ingredient set and amounts would face direct literal-claim risk if the patent were enforceable. The claim becomes less relevant where the manufacturer uses a different carbomer, materially different excipient levels, or a nonaqueous or non-gel vehicle.

Xanthan gum and hydroxypropylethylcellulose gel

Claim 6 recites, per gram:

Ingredient	Amount
Adapalene	3 mg
Xanthan gum	8 mg
Hydroxypropylethylcellulose	10 mg
Disodium edetate	1 mg
Methyl paraben	2 mg
Phenoxyethanol	10 mg
Poloxamer 124	2 mg
Propylene glycol	40 mg
Purified water	Quantity sufficient to 1 g

This claim captures a different rheology system and prevents simple substitution of Carbomer 940 for the xanthan-cellulose combination where the claimed composition is otherwise reproduced.

How do the cream-gel claims differ from the aqueous-gel claims?

Claims 7 through 12 cover an aqueous cream gel rather than a conventional aqueous gel. The claims do not require the broad excipient categories in claim 1, but the dependent claims identify specific cream-gel systems.

Simulgel 600 PHA formulation

Claim 10 recites:

Adapalene: 3 mg/g.
Simulgel 600 PHA: 20 mg/g.
Cetearyl isononanoate: 100 mg/g.
Disodium edetate: 1 mg/g.
Methyl paraben: 2 mg/g.
Poloxamer 124: 2 mg/g.
Propylene glycol: 40 mg/g.
Purified water to 1 g.

Pemulen TR1 formulation

Claim 12 recites:

Adapalene: 3 mg/g.
Pemulen TR1: 5 mg/g.
Mineral oil: 120 mg/g.
Disodium edetate: 1 mg/g.
Methyl paraben: 2 mg/g.
Propyl paraben: 1 mg/g.
Poloxamer 124: 2 mg/g.
Propylene glycol: 40 mg/g.
Sodium hydroxide to pH 5.0 ± 0.3.
Purified water to 1 g.

These claims are formulation-specific. They are more vulnerable to design-around than claim 7 because the detailed claims depend on named commercial excipients and narrow quantitative compositions.

What do the cream claims cover?

Claim 13 covers a 0.3% adapalene cream in which adapalene is the only active anti-acne ingredient. Claim 15 expands the cream vehicle to include:

Silicone oils.
Siliconized oily or fatty substances.
Non-siliconized fatty substances.
Vegetable oils.
Mineral oils.
Animal oils.
Synthetic oils.

Claim 16 identifies narrower vehicle components, including:

Perhydrosqualene.
Cyclomethicone.
PEG-20 methyl glucose sesquistearate.
Methyl glucose sesquistearate.

Claim 18 recites a detailed cream formulation containing Carbomer 934, PEG-20 methyl glucose sesquistearate, methyl glucose sesquistearate, glycerol, cyclomethicone, perhydrosqualene, preservatives, and a pH adjusted to 6.5 ± 0.3.

The claim architecture gives the patent coverage across both water-continuous and oil-containing topical systems. It does not, however, cover every 0.3% adapalene cream. The accused product must satisfy the claimed vehicle and active-ingredient limitations for literal infringement.

What do the aqueous-lotion claims protect?

Claim 19 covers a 0.3% adapalene aqueous lotion used as acne monotherapy. Claim 21 identifies broad functional excipient classes, including humectants, penetration promoters, propylene glycol, PEG 400, mineral oils, lipophilic substances, caprylic/capric triglycerides, and emulsifiers.

Claims 23 through 28 and claim 39 recite specific lotion compositions. The formulas use combinations of:

Simulgel 600 PHA.
Steareth 21.
Glyceryl and PEG 100 stearate.
Perhydrosqualene.
Cetearyl isononanoate.
Glycerine.
Carbopol 980 NF or Carbopol 981 NF.
Ceteareth 20.
Stearyl alcohol.
Caprylic/capric triglycerides.
Cyclomethicone or dimethicone.
Poloxamer 124.
Propylene glycol.

Claim 28 appears substantively identical to claim 26 in the supplied text. That duplication should be checked against the issued patent and any certificate of correction. It may reflect a transcription error, an issued-claim duplication, or a difference omitted from the supplied version.

What does the spray claim cover?

Claim 29 is the narrowest independent claim in dosage-form terms. It requires:

Treatment of acne.
Topical administration.
A pharmaceutical spray solution.
0.3% adapalene.
Adapalene as the only active anti-acne ingredient.
Caprylic/capric triglycerides in the spray medium.

Claim 33 specifies:

Ingredient	Amount
Adapalene	0.3% w/w
Caprylic/capric triglycerides	50% w/w
N-methylpyrrolidone	3% w/w
Ethanol	Quantity sufficient to 100%

A spray formulation without caprylic/capric triglycerides would have a strong non-infringement position against claim 29. A formulation using those triglycerides but a different solvent system could avoid claim 33 while remaining within claim 29 if all other limitations are met.

How does “consisting essentially of” affect infringement analysis?

The phrase “consisting essentially of” creates an open-ended composition limitation with a materiality boundary. The formulation may contain unrecited ingredients, but those ingredients must not materially alter the basic and novel characteristics of the claimed composition.

For these claims, the basic characteristics likely include:

0.3% adapalene delivery.
Topical treatment of acne.
Adapalene monotherapy.
The claimed dosage-form structure.
The relevant vehicle and skin-delivery properties.

An unlisted preservative or pH adjuster would generally be easier to reconcile with the claim than a second anti-acne active. Benzoyl peroxide, clindamycin, erythromycin, salicylic acid, or another recognized acne active would create a direct conflict with the express “only active anti-acne ingredient” limitation.

The analysis is claim-specific. An ingredient can be pharmacologically active in another context without necessarily being an “active anti-acne ingredient,” but relying on that distinction would create litigation risk.

When did US Patent 7,868,044 lose exclusivity?

Event	Date or status
Patent issued	January 11, 2011
Patent term basis	20 years from the applicable nonprovisional filing date
Nominal term endpoint	2021, based on the underlying filing history
Current commercial status	No prospective exclusivity value after nominal expiration
Regulatory consequence	ANDA applicants no longer need to defer launch because of this patent alone

The exact enforceable endpoint depends on the USPTO’s recorded patent-term adjustment, any terminal disclaimer, and the patent’s full priority chain. For business planning, the patent should be treated as expired unless an official USPTO record shows an unusual surviving term. FDA patent listings do not independently extend an expired patent’s enforceability.

What is the Orange Book status of US 7,868,044?

The relevant reference product is Differin 0.3% gel, associated with Galderma Laboratories and an FDA-approved adapalene 0.3% topical product. The FDA Orange Book historically listed patents associated with the Differin 0.3% product and its approved use and formulation profile.

The Orange Book’s role is regulatory, not substantive patent adjudication. A listed patent may trigger a certification requirement for an ANDA applicant, but the listing does not establish that every listed claim covers every generic product. Once the patent expires, it no longer creates a regulatory delay for approval or launch.

A 0.3% adapalene generic may still need to address other listed patents, labeling requirements, and any exclusivity associated with the reference product. The status of each patent must be checked against the current FDA Orange Book entry for the specific NDA.

Which companies challenged the Differin 0.3% patent estate?

The public generic market for adapalene 0.3% has included abbreviated new drug application activity by manufacturers such as Teva Pharmaceuticals and Taro Pharmaceuticals. Generic applicants typically use Paragraph IV certifications against unexpired listed patents or Paragraph III certifications where patents have expired.

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. Under the Hatch-Waxman framework, the NDA holder can file suit within 45 days, triggering a statutory stay of ANDA approval for up to 30 months, subject to statutory exceptions and court developments.[2]

US 7,868,044 is no longer the principal litigation barrier because its nominal term has ended. Earlier Paragraph IV disputes involving adapalene products may have concerned different patents, including combination-product or formulation patents. Patent-by-patent attribution is required because a Paragraph IV notice against a Differin product does not necessarily target US 7,868,044.

What other patents are relevant to adapalene?

The commercial adapalene landscape includes several distinct patent categories.

Patent category	Representative relevance
Original adapalene and early topical compositions	Broad historical protection around the active ingredient and early dermatological compositions
0.3% adapalene formulations	Higher-strength gel, cream, lotion, and related formulation systems
Adapalene and benzoyl peroxide combinations	Separate combination-product patents, including US 6,878,731
Delivery and vehicle patents	Solubilization, dispersion, rheology, skin penetration, stability, and cosmetic acceptability
Method-of-use patents	Acne treatment, dosing, application regimens, or use in defined patient populations
Manufacturing patents	Synthesis, purification, particle-size control, polymorph, and formulation processing

US 6,878,731 is associated with adapalene and benzoyl peroxide combination compositions and is analytically separate from US 7,868,044. A manufacturer launching adapalene monotherapy may avoid the combination patent while still needing to assess formulation and method claims. Conversely, a combination product may avoid the “only active anti-acne ingredient” limitation in US 7,868,044 but encounter the combination-product estate.

The original adapalene patent estate is largely historical because early patents reached expiration before or around the initial generic-entry period. Later patents focused on specific concentrations, vehicles, combinations, or delivery technologies.

Is there biosimilar risk for adapalene?

There is no biosimilar pathway for adapalene. Adapalene is a small-molecule drug regulated through the generic-drug framework under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The relevant competitors are ANDA applicants, not biosimilar applicants under the Biologics Price Competition and Innovation Act.[3]

Competitive risk therefore depends on:

ANDA approval.
Paragraph III or Paragraph IV patent certifications.
Product-specific formulation similarity.
Bioequivalence and comparative clinical endpoint requirements.
State substitution rules.
Manufacturing capacity and commercial distribution.

How strong is the patent estate for 0.3% adapalene?

Strengths

The patent covers the commercially important 0.3% concentration.
Independent claims span several topical dosage forms.
The “only active anti-acne ingredient” limitation aligns with adapalene monotherapy products.
Dependent claims identify commercially plausible excipient systems.
Formulation claims can complicate direct copying even where the active ingredient is unprotected.

Weaknesses

The patent is expired on its nominal term.
The claims are method claims, requiring proof of topical administration for acne treatment.
The 0.3% concentration excludes 0.1% adapalene products.
Combination products may avoid the sole-active limitation.
Many dependent claims require exact excipient combinations and quantities.
Modern generic products may use different polymers, preservatives, emulsifiers, or delivery systems.
The patent does not create biosimilar-style market exclusivity.

If evaluated during its enforceable term, the broadest risk was concentrated in claim 1 for aqueous gels and claim 19 for lotions. The most practical design-around strategies were changing the concentration, adding a second active, selecting a different vehicle, or moving to a formulation outside the claimed excipient categories. After expiration, those strategies remain relevant for other patents and product differentiation but are no longer needed to avoid US 7,868,044.

What generic launch scenarios exist for 0.3% adapalene?

Scenario	Patent impact of US 7,868,044
0.3% adapalene aqueous gel	No current barrier from this expired patent
0.3% adapalene cream	No current barrier from this expired patent
0.3% adapalene lotion	No current barrier from this expired patent
0.3% adapalene spray	No current barrier from this expired patent
0.1% adapalene gel	Outside the 0.3% limitation
Adapalene plus benzoyl peroxide	Outside the sole-active limitation, but other patents may apply
New delivery system	Outside many dependent formulation claims, subject to other patents
OTC switch or retail product	Regulatory status depends on the applicable FDA monograph or approved application

The principal remaining barriers are regulatory approval, formulation development, manufacturing scale, supply of qualified excipients, stability data, labeling, and commercial access. US 7,868,044 does not provide a current US exclusivity barrier by itself.

What manufacturing and geographic barriers remain?

The patent claims do not appear to impose a meaningful current manufacturing barrier because they protect treatment methods and formulations rather than a uniquely indispensable production process. A manufacturer may still face:

Process patents for adapalene synthesis or purification.
Particle-size and dispersion know-how.
Stability and preservative-control requirements.
Supplier qualification for polymers and emulsifiers.
Device patents covering spray delivery.
Regulatory requirements in jurisdictions where counterpart patents remain active.

US expiration does not automatically terminate foreign counterparts. European, Canadian, Asian, and other national patents must be assessed independently. The geographic freedom-to-operate conclusion for the United States cannot be extended to foreign markets.

Key Takeaways

US 7,868,044 covers topical acne treatment with 0.3% adapalene as the sole active anti-acne ingredient.
The patent spans aqueous gels, cream gels, creams, aqueous lotions, and spray solutions.
Claims 1, 7, 13, 19, and 29 are the principal independent claim families.
Claims 3-6, 10, 12, 18, 24, 26, 28, 33, and 39 provide detailed formulation coverage.
The claims do not broadly cover adapalene at all concentrations.
Combination products containing benzoyl peroxide or antibiotics generally fall outside the sole-active limitation.
The patent’s nominal US term ended in 2021, eliminating it as a current generic-entry barrier.
Adapalene is a small molecule, so generic ANDA competition applies rather than biosimilar competition.
Separate patents may still affect adapalene/benzoyl peroxide combinations, delivery systems, manufacturing, or foreign markets.
The supplied version of claim 28 duplicates claim 26 and should be checked against the issued patent and any certificate of correction.

FAQs

Does US 7,868,044 cover Differin 0.1% gel?

No. The claims require adapalene at 0.3% by weight. A 0.1% adapalene product falls outside that express concentration limitation, although other patents or regulatory protections may be relevant.

Does adding benzoyl peroxide avoid US 7,868,044?

Generally, yes, because the claims require adapalene to be the only active anti-acne ingredient. An adapalene-benzoyl peroxide product must still be assessed against separate combination-product patents.

Can a generic use Carbopol in a 0.3% adapalene gel?

Yes, but the exact Carbopol grade, quantity, formulation structure, and applicable patent claims must be assessed. Claims 1, 40, and 41 specifically address aqueous gels containing carbomer, with claim 41 narrowing to Carbomer 940.

Is US 7,868,044 still a Paragraph IV litigation risk?

It is unlikely to create a current US Paragraph IV barrier after expiration. Historical ANDA litigation may still be relevant for settlement, launch timing, damages, or interpretation of related patents.

Does expiration of the US patent eliminate foreign adapalene patent risk?

No. Patent rights are territorial. US expiration does not determine the status of European, Canadian, Japanese, Chinese, or other national counterparts.

References

U.S. Patent and Trademark Office. (2011). U.S. Patent No. 7,868,044, pharmaceutical compositions based on adapalene.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications.
U.S. Food and Drug Administration. (n.d.). Differin (adapalene) gel, 0.3% prescribing information.
U.S. Patent and Trademark Office. (n.d.). Patent Center: Patent term adjustment and prosecution records.
U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,878,731, pharmaceutical compositions comprising adapalene and benzoyl peroxide.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	02 03070	Mar 12, 2002

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	038924	⤷ Start Trial
Austria	417610	⤷ Start Trial
Austria	432072	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,868,044

Summary for Patent: 7,868,044